Insulin-mediated Reduction of Whole Body Protein Breakdown. Dose-response Effects on Leucine Metabolism in Postabsorptive Men
Overview
Affiliations
In vivo effects of insulin on plasma leucine and alanine kinetics were determined in healthy postabsorptive young men (n = 5) employing 360-min primed, constant infusions of L-[1-13C]leucine and L-[15N]alanine during separate single rate euglycemic insulin infusions. Serum insulin concentrations of 16.4 +/- 0.8, 29.1 +/- 2.7, 75.3 +/- 5.0, and 2,407 +/- 56 microU/ml were achieved. Changes in plasma 3-methyl-histidine (3-MeHis) were obtained as an independent qualitative indicator of insulin-mediated reduction in proteolysis. Hepatic glucose output was evaluated at the lowest insulin level using D-[6,6-2H2]glucose. The data demonstrate a dose-response effect of insulin to reduce leucine flux, from basal values of 77 +/- 1 to 70 +/- 2, 64 +/- 3, 57 +/- 3, and 52 +/- 4 mumol(kg X h)-1 at the 16, 29, 75, and 2,407 microU/ml insulin levels, respectively (P less than 0.01). A parallel, progressive reduction in 3-MeHis from 5.8 +/- 0.3 to 4.3 +/- 0.3 microM was revealed. Leucine oxidation estimated from the 13C-enrichment of expired CO2 and plasma leucine (12 +/- 1 mumol[kg X h]-1) and from the 13C-enrichment of CO2 and plasma alpha-ketoisocaproate (19 +/- 2 mumol[kg X h]-1) increased at the 16 microU/ml insulin level to 16 +/- 1 and 24 +/- 2 mumol(kg X h)-1, respectively (P less than 0.05 for each), but did not increase at higher insulin levels. Alanine flux (206 +/- 13 mumol(kg X h)-1) did not increase during the clamp, but alanine de novo synthesis increased in all studies from basal rates of 150 +/- 13 to 168 +/- 23, 185 +/- 21, 213 +/- 29, and 187 +/- 15 mumol(kg X h)-1 at 16, 29, 75, and 2,407 microU/ml insulin levels, respectively (P less than 0.05). These data indicate the presence of insulin-dependent suppression of leucine entry into the plasma compartment in man secondary to a reduction in proteolysis and the stimulation of alanine synthesis during euglycemic hyperinsulinemia.
Fujita S, Hironaka K, Karasawa Y, Kuroda S iScience. 2024; 27(6):109833.
PMID: 39055606 PMC: 11270033. DOI: 10.1016/j.isci.2024.109833.
Proteomic signatures for identification of impaired glucose tolerance.
Carrasco-Zanini J, Pietzner M, Lindbohm J, Wheeler E, Oerton E, Kerrison N Nat Med. 2022; 28(11):2293-2300.
PMID: 36357677 PMC: 7614638. DOI: 10.1038/s41591-022-02055-z.
Sadana P, Edler M, Aghayev M, Arias-Alvarado A, Cohn E, Ilchenko S Am J Physiol Endocrinol Metab. 2022; 323(6):E480-E491.
PMID: 36223521 PMC: 9722254. DOI: 10.1152/ajpendo.00158.2022.
Vanweert F, Schrauwen P, Phielix E Nutr Diabetes. 2022; 12(1):35.
PMID: 35931683 PMC: 9356071. DOI: 10.1038/s41387-022-00213-3.
James H, Gonsalves W, Manjunatha S, Dasari S, Lanza I, Klaus K Diabetes. 2022; 71(8):1636-1648.
PMID: 35621914 PMC: 9490357. DOI: 10.2337/db22-0079.